John Sidney Selected Research

Epitopes

7/2022	Immunodominant MHC-II (Major Histocompatibility Complex II) Restricted Epitopes in Human Apolipoprotein B.
10/2021	CD8+ T cells specific for cryptic apoptosis-associated epitopes exacerbate experimental autoimmune encephalomyelitis.
10/2021	Profiling Human Cytomegalovirus-Specific T Cell Responses Reveals Novel Immunogenic Open Reading Frames.
1/2021	SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19.
1/2021	Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases.
1/2021	Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs.
1/2021	Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer.
12/2020	Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases.
11/2020	Identification of Novel Yellow Fever Class II Epitopes in YF-17D Vaccinees.
10/2020	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John Sidney Research Topics

Disease

62	Infections 11/2021 - 01/2004
28	Neoplasms (Cancer) 01/2021 - 01/2002
10	Hypersensitivity (Allergy) 01/2018 - 01/2010
9	Dengue (Dengue Fever) 01/2018 - 01/2013
8	COVID-19 01/2022 - 12/2020
8	HIV Infections (HIV Infection) 07/2013 - 04/2005
7	Smallpox (Variola) 12/2013 - 01/2005
6	Virus Diseases (Viral Diseases) 01/2022 - 08/2008
6	Viremia 01/2017 - 06/2005
5	Atherosclerosis 07/2022 - 01/2013
5	Rheumatoid Arthritis 01/2021 - 07/2012
5	Tuberculosis (Tuberculoses) 01/2018 - 09/2007
5	Toxoplasmosis 01/2017 - 05/2010
5	Melanoma (Melanoma, Malignant) 12/2015 - 03/2003
5	Acquired Immunodeficiency Syndrome (AIDS) 05/2013 - 11/2002
4	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 10/2009
4	Celiac Disease (Celiac Sprue) 01/2017 - 02/2008
4	Vaccinia 12/2013 - 09/2005
3	Human Influenza (Influenza) 01/2019 - 05/2010
3	Disease Progression 01/2019 - 06/2008
3	Parkinson Disease (Parkinson's Disease) 01/2019 - 01/2017
3	Tetanus 01/2018 - 01/2017
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2018 - 06/2012
3	Communicable Diseases (Infectious Diseases) 01/2018 - 01/2002
3	Malaria 11/2017 - 07/2006
3	Persistent Infection 01/2014 - 09/2005
2	Vasculitis (Vasculitides) 01/2022 - 01/2020
2	Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) 01/2022 - 05/2015
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 10/2021 - 01/2004
2	Lung Diseases (Lung Disease) 01/2021 - 01/2020
2	Yellow Fever 11/2020 - 01/2013
2	Asthma (Bronchial Asthma) 01/2018 - 08/2012
2	Rhinitis 01/2018 - 08/2012
2	Drug-Related Side Effects and Adverse Reactions 01/2015 - 06/2012
2	Coinfection 10/2014 - 04/2006
2	Infectious Ectromelia 09/2014 - 01/2005
2	Leukemia 07/2014 - 10/2012
2	Cowpox 12/2013 - 01/2005
2	Multiple Sclerosis 07/2013 - 01/2004
2	Arenaviridae Infections 06/2010 - 05/2010
2	Lymphocytic Choriomeningitis 05/2010 - 12/2009
2	Fever (Fevers) 05/2010 - 12/2009
2	Aseptic Meningitis 05/2010 - 12/2009
2	Latent Tuberculosis 01/2010 - 09/2007
2	Chagas Disease (American Trypanosomiasis) 01/2008 - 04/2005
2	Ectromelia (Phocomelia) 07/2006 - 01/2005
1	Coronary Artery Disease (Coronary Atherosclerosis) 07/2022
1	Common Cold 01/2022
1	Encephalitis (Encephalitis, Rasmussen) 11/2021

Drug/Important Bio-Agent (IBA)

85	EpitopesIBA 07/2022 - 01/2002
56	Peptides (Polypeptides)IBA 01/2022 - 07/2002
49	VaccinesIBA 01/2022 - 01/2002
43	AntigensIBA 01/2021 - 01/2004
28	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 07/2022 - 07/2002
28	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2003
9	CytokinesIBA 07/2022 - 11/2004
8	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 02/2008
8	AutoantigensIBA 01/2019 - 01/2004
6	Histocompatibility Antigens Class IIBA 01/2019 - 11/2002
6	Antiviral Agents (Antivirals)IBA 01/2019 - 11/2004
5	HLA-B Antigens (HLA-B)IBA 01/2014 - 04/2006
5	HLA-A*02:01 antigenIBA 06/2012 - 04/2005
4	Immunoglobulin G (IgG)IBA 01/2021 - 01/2013
4	HLA-A Antigens (HLA-A)IBA 01/2019 - 05/2010
4	AllergensIBA 01/2018 - 01/2010
4	Glycoproteins (Glycoprotein)IBA 01/2013 - 09/2003
3	Apolipoproteins B (ApoB)IBA 07/2022 - 04/2017
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2022 - 01/2015
3	NucleoproteinsIBA 01/2022 - 01/2019
3	Interferon-gamma (Interferon, gamma)IBA 11/2021 - 05/2004
3	Viral RNAIBA 11/2021 - 06/2009
3	Viral AntigensIBA 01/2020 - 12/2015
3	HLA-DRB1 Chains (HLA DRB1)IBA 10/2016 - 01/2010
3	EnzymesIBA 01/2015 - 05/2004
3	CaspasesIBA 07/2013 - 12/2007
3	Glutens (Glutelin)IBA 01/2013 - 02/2008
3	Neutralizing AntibodiesIBA 01/2013 - 09/2006
2	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2022 - 01/2020
2	COVID-19 VaccinesIBA 03/2021 - 01/2021
2	BNT162 VaccineIBA 03/2021 - 01/2021
2	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2019 - 10/2016
2	AntibodiesIBA 01/2019 - 08/2014
2	Tetanus Toxoid (Vaccine, Tetanus)FDA Link 01/2018 - 01/2017
2	Attenuated VaccinesIBA 12/2017 - 01/2017
2	ProteomeIBA 11/2017 - 12/2007
2	oxidized low density lipoproteinIBA 04/2017 - 01/2013
2	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 05/2009
2	SynucleinsIBA 01/2017 - 01/2017
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 12/2015 - 01/2012
2	Immunoglobulin E (IgE)IBA 01/2014 - 07/2012
2	HLA-B27 Antigen (HLA B27 Antigen)IBA 05/2013 - 11/2007
2	Pharmaceutical PreparationsIBA 10/2012 - 06/2012
2	A-factor (Streptomyces)IBA 06/2007 - 01/2004
2	Immunodominant EpitopesIBA 04/2005 - 01/2005
2	Amino Acids FDA Link 10/2004 - 03/2004
1	Myeloblastin (Proteinase 3)IBA 01/2022
1	HLA-DPB1 antigen (HLA DPB1)IBA 01/2022
1	CD40 Ligand (CD40L)IBA 11/2021

Therapy/Procedure

14	Immunotherapy 01/2019 - 01/2002
13	Therapeutics 01/2021 - 11/2004